干扰素雾化与利巴韦林治疗婴幼儿疱疹性咽峡炎的临床疗效与安全性对比观察

The contrast observation of the clinical efficacy and safety of interferon nebulization and ribavirin in the treatment of infantile herpes angina

目的探讨干扰素雾化与利巴韦林治疗婴幼儿疱疹性咽峡炎临床疗效及安全性。方法选取2016年1~12月我院住院收治80例疱疹性咽峡炎患儿为研究对象,采用信封分组法将患儿分为A组和B组,A组给予对症及加用注射用重组人干扰素α1b雾化吸入治疗,B组给予对症及利巴韦林静滴治疗,比较两组患儿临床疗效、疱疹消失时间、体温恢复时间、住院时间及并发症发生情况。结果 A组患儿治疗总有效率显著高于B组(97.50%vs 80.00%,P<0.05)。A组患儿疱疹消失时间、体温恢复时间、住院时间均短于B组[(3.4±1.1)d vs(4.9±1.4)d,(2.1±0.8)d vs(3.6±1.0)d,(5.4±1.0)d vs(6.8±1.3)d,P<0.05]。两组患儿治疗期间恶心呕吐、贫血、乏力、头痛药物不良反应发生率比较差异无统计学意义(P>0.05)。结论干扰素雾化治疗婴幼儿疱疹性咽峡炎可缩短患儿临床症状改善时间,提高临床疗效,具有较高治疗效果和用药安全性。

Objective To evaluate the clinical efficacy and safety of interferon nebulization and Ribavirin in the treatment of infantile herpes angina. Methods 80 case of Herpes angina were selected as studying object,who were in children of our hospital from January 2016 to December 2016, divided into A group and B group.Group A was given symptomatic treatment combined with recombinant human interferon α 1b inhalation therapy. Group B was given symptomatic treatment combined with intravenous drip Ribavirin. The clinical curative effect, the disappearance time of herpes, the recovery time of body temperature, the length of hospital stay and compl.ications were compared between the two groups. Results The total effective rate in the A group was significantly higher than that in the B group （97.50% vs 80.00%, P 〈 0.05）. Herpes disappearance time, body temperature recovery time, hospitalization time in the A group were shorter than the B group[ （ 3.4 ± 1.1 ） d vs. （ 4.9 ± 1.4 ） d, （ 2.1 ± 0.8 ） d vs. （ 3.6 ± 1.0 ） d, （ 5.4 ± 1.0 ） d vs. （ 6.8 ± 1.3 ） d, P 〈 0.05]. There was no significant difference in incidence rate of adverse drug reactions （nausea, vomiting, anemia, fatigue, headache） between the two groups （P 〉 0.05）. Conclusion Interferon nebulization treatment of infantile herpes angina can shorten the time to improve clinical symptoms in children, improve clinical efficacy, with high therapeutic effect and drug safety.